{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:14:35Z","timestamp":1789168475879,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T00:00:00Z","timestamp":1728777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13555-024-01270-5","type":"journal-article","created":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T20:20:00Z","timestamp":1728850800000},"page":"2987-2997","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis\u2014IL PSO (Italian Landscape Psoriasis)"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Ibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"Cascio Ingurgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Campoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G.","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M.","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Minuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,13]]},"reference":[{"issue":"10281","key":"1270_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6.","journal-title":"Lancet"},{"issue":"3","key":"1270_CR2","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","volume":"85","author":"NH Shear","year":"2021","unstructured":"Shear NH, Betts KA, Soliman AM, et al. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data. J Am Acad Dermatol. 2021;85(3):572\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.057.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1270_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114\u201323.","journal-title":"Br J Dermatol"},{"key":"1270_CR4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/jdv.18913","volume":"37","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Malagoli P, Angileri RG, Bardazzi F, Bernardini N, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study\u2014IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023;37:1017\u201327.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1270_CR5","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.3390\/jcm13092552","volume":"13","author":"M Megna","year":"2024","unstructured":"Megna M, Balato A, Caccavale S, Cacciapuoti S, Calabrese G, Di Brizzi EV, Di Costanzo L, Manzo R, Marino V, Puca RV, Romano F, Sarno O, di Luzio GS, Lembo S. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 3-year multicenter study. J Clin Med. 2024;13(9):2552.","journal-title":"J Clin Med"},{"issue":"2","key":"1270_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40744-024-00644-7","volume":"11","author":"P Thilakarathne","year":"2024","unstructured":"Thilakarathne P, Schubert A, Peterson S, Noel W, Patel BP, Hassan F. Comparing efficacy of guselkumab versus ustekinumab in patients with psoriatic arthritis: an adjusted comparison using individual patient data from the DISCOVER and PSUMMIT trials. Rheumatol Ther. 2024;11(2):457\u201374.","journal-title":"Rheumatol Ther"},{"issue":"Suppl. 1 to No.","key":"1270_CR7","first-page":"1","volume":"157","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Fargnoli MC, Amerio P, Argenziano G, Bardazzi F, Bianchi L, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 2022;157(Suppl. 1 to No. 1):1\u201378.","journal-title":"Ital J Dermatol Venerol."},{"key":"1270_CR8","unstructured":"European Medicines Agency. Tremfya (guselkumab): summary of product characteristics. 2017[cited 2024 June 1]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tremfya."},{"issue":"6","key":"1270_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15485","volume":"35","author":"F Bardazzi","year":"2022","unstructured":"Bardazzi F, Viviani F, Filippi F, Carpanese MA, Piraccini BM, Abbenante D. The legs: an underestimated difficult-to-treat area of psoriasis. Dermatol Ther. 2022;35(6): e15485.","journal-title":"Dermatol Ther"},{"key":"1270_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.crimmu.2023.100067","volume":"4","author":"C Dong","year":"2023","unstructured":"Dong C, Lin L, Du J. Characteristics and sources of tissue-resident memory T cells in psoriasis relapse. Curr Res Immunol. 2023;4: 100067.","journal-title":"Curr Res Immunol."},{"issue":"7","key":"1270_CR11","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","volume":"141","author":"H Mehta","year":"2021","unstructured":"Mehta H, Mashiko S, Angsana J, Rubio M, Hsieh YM, Maari C, Reich K, Blauvelt A, Bissonnette R, Mu\u00f1oz-El\u00edas EJ, Sarfati M. Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab. J Invest Dermatol. 2021;141(7):1707-1718.e9.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"1270_CR12","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1111\/jdv.19135","volume":"37","author":"L Mastorino","year":"2023","unstructured":"Mastorino L, Susca S, Cariti C, et al. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients. J Eur Acad Dermatol Venereol. 2023;37(9):1848\u201353. https:\/\/doi.org\/10.1111\/jdv.19135.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1270_CR13","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/jdv.18474","volume":"36","author":"K Reich","year":"2022","unstructured":"Reich K, Gordon KB, Strober B, Langley RG, Miller M, Yang YW, et al. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline psoriasis area and severity index, and baseline Investigator\u2019s global assessment scores predict complete skin clearance. J Eur Acad Dermatol Venereol. 2022;36:2393\u2013400.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1270_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","volume":"154","author":"P Foley","year":"2018","unstructured":"Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, et al. Efficacy of guselkumab compared with Adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2018;154(6):676\u201383.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1270_CR15","doi-asserted-by":"publisher","first-page":"2220849","DOI":"10.1080\/09546634.2023.2220849","volume":"34","author":"D Orsini","year":"2023","unstructured":"Orsini D, Gargiulo L, Ibba L, et al. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers. J Dermatolog Treat. 2023;34(1):2220849. https:\/\/doi.org\/10.1080\/09546634.2023.2220849.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1270_CR16","doi-asserted-by":"publisher","first-page":"2199108","DOI":"10.1080\/09546634.2023.2199108","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Alfano A, Cascio Ingurgio R, Narcisi A, Costanzo A, Valenti M. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J Dermatolog Treat. 2023;34(1):2199108.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1270_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15378","volume":"35","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Susca S, Megna M, Siliquini N, Quaglino P, Ortoncelli M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. 2022;35(5): e15378.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1270_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.18594","volume":"37","author":"A Narcisi","year":"2023","unstructured":"Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicenter retrospective study\u2014IL PSO (ITALIAN LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023;37(1):93\u2013103.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1270_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000519924","volume":"238","author":"KA Drerup","year":"2022","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238:615\u20139.","journal-title":"Dermatology"},{"issue":"4","key":"1270_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Tsai TF, Langley RG, Miller M, Shen YK, You Y, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86(4):827\u201334.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1270_CR21","doi-asserted-by":"publisher","first-page":"2241585","DOI":"10.1080\/09546634.2023.2241585","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Vignoli CA, Fiorillo G, Valenti M, Costanzo A, Narcisi A. Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study. J Dermatolog Treat. 2023;34(1):2241585.","journal-title":"J Dermatolog Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01270-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01270-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01270-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T03:15:04Z","timestamp":1731467704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01270-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,13]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01270-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,13]]},"assertion":[{"value":"14 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mario Valenti has been a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, UCB-Pharma, Difa-Cooper, Almirall, AbbVie and Boehringer Ingelheim. Luciano Ibba has been a consultant for Almirall. Piergiorgio Malagoli has been a speaker for AbbVie, Lilly, Novartis, Janssen-Cilag, Celgene, Leopharma, and Almirall. Andrea Carugno has been speaker and\/or consultant for Almirall, Amgen, Abbvie, Boehringer-Ingelheim, Eli-Lilly, Leopharma, Jansse-Cilag, Novartis, UCB Pharma. Francesca M. Gaiani acted as a speaker or consultant for Novartis, Abbvie, Eli Lilly, Celgene, LeoPharma, and Almirall. Carlo G. Carrera has served as a board participant or speaker for Abbvie, Lilly, Janssen, Novartis, Celgene, Almirall, and Leopharma. Angelo V. Marzano reports consultancy\/advisory boards disease-relevant honoraria from AbbVie, Boehringer-Ingelheim, Novartis, Pfizer, Sanofi and UCB. Antonio Costanzo has been a consultant and\/or speaker for Abb-Vie, Almirall, Amgen, Janssen, Leo Pharma, Eli Lilly, Galderma, Boehringer, Novartis, Pfizer, Sandoz, and UCB. Alessandra Narcisi has served on advisory boards, received honoraria for lectures and research grants from Almirall, Abbvie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi\u2010Genzyme, Amgen and Boehringer Ingelheim. Davide Strippoli has been a consultant and\/or speaker for Abbvie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer. Marco Campoli, Nicola Zerbinati, Ruggero Cascio Ingurgio and Federica Mola, have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional review board approval was exempted as the study protocol did not deviate from standard clinical practice. All patients received ixekizumab as part of routine clinical practice in accordance with European guidelines. All included patients had provided written consent for retrospective study of data collected during routine clinical practice (demographics, clinical scores). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}